FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	OMB APPROVAL
16	

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*						2. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS INC							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
LINK WAX					ALXN]						2	X Directo	r	10% Ov	ner		
(1.0)												Officer below)	(give title	Other (s below)	pecify		
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year)						bciow)		below)			
C/O ALEXION PHARMACEUTICALS					05/11/2011												
352 KNOTTER DRIVE						4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable				
(Charan)						4. If Americanent, Date of Original Filed (Month/Ddy/fedf)							Line)				
(Street) CHESHIRE CT 06410										X Form filed by One Reporting Person							
CHESTINE CI 00410											Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)														
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					Execution Date,			3. Transaction Code (Instr. 8) 3. 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) 5)				5. Amour Securitie Beneficia Owned F	s Form ally (D) collowing (I) (II	n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code V	Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)		Instr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																
			(e.	g., puts	, call	s, warra	ınts	, options,	convertib	ole secu	rities)						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	cise (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)				
Option to Purchase Common Stock	\$98.86	05/11/2011		A		2,786 ⁽¹⁾		08/11/2011	05/11/2021	Common Stock, par value \$.0001 per share	2,786	\$0	2,786	D			

Explanation of Responses:

1. These options will vest in four quarterly installments during the one year period commencing on May 11, 2011 and ending on May 11, 2012.

/s/ Max Link

05/13/2011

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.